Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 4/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | P2RX4 | Q99571 | 4/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HRH1 | P35367 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL523372 | 0.95 | ALOX5 (0.39) | ALOX5AKR1B1THRBTDP1MEN1 | |
| Bromide SCHEMBL27743791 | 0.93 | ALOX5 (0.38) | ALOX5AKR1B1THRBTDP1MEN1 | |
| Bromomethane SCHEMBL15709779 | 0.87 | ALOX5 (0.35) | ALOX5AKR1B1THRBTDP1MEN1 | |
| Bromomethane SCHEMBL207850 | 0.87 | KMT2A (0.37) | ALOX5AKR1B1THRBTDP1MEN1 | |
| SCHEMBL524258 | 0.83 | KMT2A (0.39) | ALOX5AKR1B1THRBTDP1MEN1 | |
| Propanol SCHEMBL27803554 | 0.80 | KMT2A (0.36) | ALOX5AKR1B1THRBTDP1MEN1 | |
| SCHEMBL10974812 | 0.79 | AKR1B1 (0.43) | ALOX5AKR1B1THRBTDP1KMT2A | |
| SCHEMBL5863624 | 0.78 | ALOX5 (0.35) | ALOX5AKR1B1THRBTDP1P2RX4 | |
| Bromomethane SCHEMBL208551 | 0.77 | ALOX5 (0.39) | ALOX5AKR1B1THRBTDP1P2RX4 | |
| Bromomethane SCHEMBL208816 | 0.77 | THRB (0.55) | ALOX5AKR1B1THRBTDP1P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 519 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100015061-A1 | Pharmaceutical Compositions Based on Anticholinergics and Andolast | Boehringer Ingeheim International GmnH (DE) | 2010-01-21 | — | — | US | claimed |
| EP-1978955-A1 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND ANDOLAST | Boehringer Ingelheim International GmbH (DE) | 2008-10-15 | — | — | EP | claimed |
| EP-1858554-A2 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND PDE 5-INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2007-11-28 | — | — | EP | claimed |
| WO-2007077164-A1 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND ANDOLAST | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-12 | — | — | WO | claimed |
| US-20060204450-A1 | Pharmaceutical Compositions Based On Anticholinergics and PDE 5-Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-09-14 | — | — | US | claimed |
| WO-2006094924-A2 | NEW PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND PDE 5-INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-09-14 | — | — | WO | claimed |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2024-04-04 | — | — | US | disclosed |
| CN-112279808-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-112250627-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-02-02 | — | — | CN | disclosed |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2022-01-06 | — | — | US | disclosed |
| US-11046706-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2021-06-29 | — | — | US | disclosed |
| US-10745411-B2 | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-08-18 | — | — | US | disclosed |
| US-20050267106-A1 | New enentiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-01 | — | — | US | disclosed |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2005-10-27 | — | — | US | disclosed |
| US-20050203088-A1 | Medicament combinations based on scopine- or tropene acid esters with EGFR-kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | US | disclosed |
| WO-2005079794-A1 | PHARMACEUTICAL COMPOSITIONS BASED ON ANTICHOLINERGICS AND PEGSUNERCEPT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005013994-A1 | MEDICAMENTS FOR INHALATION COMPRISING ANTICHOLINERGICS AND A BETAMIMETIC | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-17 | — | — | WO | disclosed |
| US-20050025718-A1 | Medicaments for inhalation comprising an anticholinergic and a betamimetic | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-03 | — | — | US | disclosed |
| US-20030203928-A1 | Xanthenecarboxylates, processes for preparing them, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046706-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | ALOX5 1906/4885AKR1B1 612/4885THRB 1526/4885 |
| US-10745411-B2 | Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma | CBS, DHPS, TPMT | ALOX5 976/4885AKR1B1 329/4885THRB 2325/4885 |
| US-20050267106-A1 | New enentiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments | ADRB1, ADRB2, ADRA1D | ALOX5 1200/4885AKR1B1 555/4885THRB 651/4885 |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CCR2, CCRL2, CCR1 | ALOX5 1906/4885AKR1B1 612/4885THRB 1526/4885 |
| US-20050203088-A1 | Medicament combinations based on scopine- or tropene acid esters with EGFR-kinase inhibitors | ERBB2, EGFR, ERBB3 | ALOX5 3366/4885AKR1B1 1220/4885THRB 242/4885 |
| US-20060204450-A1 | Pharmaceutical Compositions Based On Anticholinergics and PDE 5-Inhibitors | PDE5A, PDE3A, PDE3B | ALOX5 421/4885AKR1B1 1137/4885THRB 3608/4885 |
| US-20100015061-A1 | Pharmaceutical Compositions Based on Anticholinergics and Andolast | CHRM3, ACHE, CHRNA1 | ALOX5 576/4885AKR1B1 1092/4885THRB 2685/4885 |
| US-20050239778-A1 | Novel medicament combinations for the treatment of respiratory diseases | MRGPRX2, MRGPRX1, MTNR1B | ALOX5 1737/4885AKR1B1 1231/4885THRB 1632/4885 |
| US-20240109909-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | ALOX5 1906/4885AKR1B1 612/4885THRB 1526/4885 |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | CCR2, CCRL2, CCR1 | ALOX5 1906/4885AKR1B1 612/4885THRB 1526/4885 |
| US-20030203928-A1 | Xanthenecarboxylates, processes for preparing them, and their use as pharmaceutical compositions | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, F11, NR3C2 | ALOX5 2833/4885AKR1B1 1824/4885THRB 3210/4885 |
| US-20050025718-A1 | Medicaments for inhalation comprising an anticholinergic and a betamimetic | ADRB2, CHRM3, ADRB1 | ALOX5 1020/4885AKR1B1 1057/4885THRB 804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.